Abstract: The invention refers to a modular continuous flow device for automated chemical multistep synthesis under continuous flow conditions. The device comprises a plurality of different types of continuous flow modules and a valve assembly for connecting the continuous flow modules to each other in a parallel or radial manner. This arrangement allows conducting chemical reaction sequences by pre-synthesizing and intermediately storing or simultaneously synthesizing at least one intermediate product which is needed in the main synthetic reaction sequence in order to obtain the final product.

Abstract: The present invention relates to compositions comprising 1,2,4-trioxane compounds and chlorogenic acids. The invention further provides a method for the stabilization of 1,2,4-trioxane compounds against degradation, in particular against thermal degradation or degradation induced by reducing agents such as reducing carbohydrates, reducing sugars, electromagnetic radiation or heavy metal ions.

Abstract: The present invention relates to anti-cancer agents comprising 1,2,4-trioxane compounds and anti-cancer agents comprising combinations comprising 1,2,4-trioxane compounds and chlorogenic acids. The invention further provides pharmaceutical compositions comprising such anti-cancer agents, kits comprising the same as well as methods and treatment regimens of using the aforementioned anti-cancer agents, pharmaceutical compositions and kits in the treatment and prevention of cancer and for prolonging survival of subjects having cancer, in particular ovarian cancer or lung cancer.

Abstract: The present invention relates to antiviral 1,2,4-trioxane compounds and compositions comprising the same that are effective inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication, and are thus useful to treat the coronavirus disease 2019 (COVID-19). The invention further provides pharmaceutical compositions containing such antiviral compounds and antiviral compositions, and methods of using these antiviral compounds, antiviral compositions and pharmaceutical compositions in the treatment and prevention of COVID-19.

Abstract: The invention refers to a modular continuous flow device for automated chemical multistep synthesis under continuous flow conditions. The device comprises a plurality of different types of continuous flow modules and a valve assembly for connecting the continuous flow modules to each other in a parallel or radial manner. This arrangement allows conducting chemical reaction sequences by pre-synthesizing and intermediately storing or simultaneously synthesizing at least one intermediate product which is needed in the main synthetic reaction sequence in order to obtain the final product.

Abstract: The present invention is directed to a method for continuous production of dihydroartemisinin and also artemisinin derivatives derived from dihydroartemisinin by using artemisinin or dihydroartemisinic acid (DHAA) as starting material as well as to a continuous flow reactor for producing dihydroartemisinin as well as the artemisinin derivatives. It was found that the reduction of artemisinin to dihydroartemisinin in a continuous process requires a special kind of reactor and a special combination of reagents comprising a hydride reducing agent, at least one activator such as an inorganic activator, at least one solid base, at least one aprotic solvent and at least one C1-C5 alcohol.

Abstract: The invention relates to a process for the preparation of Efavirenz via an efficient transition metal catalyzed cyclization, to a device suitable to perform such process as well as to novel intermediates.

Abstract: The invention relates to a process for the preparation of Efavirenz via an efficient transition metal catalyzed cyclization, to a device suitable to perform such process as well as to novel intermediates.

Abstract: The present invention is directed to a method for continuous production of dihydroartemisinin and also artemisinin derivatives derived from dihydroartemisinin by using artemisinin or dihydroartemisinic acid (DHAA) as starting material as well as to a continuous flow reactor for producing dihydroartemisinin as well as the artemisinin derivatives. It was found that the reduction of artemisinin to dihydroartemisinin in a continuous process requires a special kind of reactor and a special combination of reagents comprising a hydride reducing agent, at least one activator such as an inorganic activator, at least one solid base, at least one aprotic solvent and at least one C1-C5 alcohol.

Abstract: Compounds and methods for double-stranded DNA cleavage of light-activated lysine conjugates are enhanced at the slightly acidic pH suitable for selective targeting of cancer cells by the presence of two amino groups of different basicities. The first amino group plays an auxiliary role enhancing solubility and affinity to DNA whereas the second amino group which is positioned next to the light-activated DNA-cleaver undergoes protonation at the desired pH threshold. Protonation results in two synergetic effects which account for the increased DNA-cleaving ability at the lower pH: tighter binding to DNA at the lower pH; and the unproductive pathway which quenches the excited state of the photocleaver through intramolecular electron transfer is eliminated once the donor amino group next to the chromophore is protonated. The utility of these molecules for phototherapy of cancer is confirmed by the drastic increase in toxicity of five conjugates against cancer cell lines upon photoactivation.